DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Didronel (Etidronate Disodium) - Published Studies


Didronel Related Published Studies

Well-designed clinical trials related to Didronel (Etidronate)

Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke. [2010.05]

Hormone replacement therapy (HRT) or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial. [2009.02]

Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]

Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. [2008.03]

Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. [2008.01]

Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial. [2006.11]

Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. [2006.02]

Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. [2006]

Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. [2005.12.31]

Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty. [2005.12]

Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. [2005.02]

Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. [2005]

Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. [2004.10.15]

Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. [2004.09]

Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. [2004.07]

Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. [2004.06]

Beneficial effect of etidronate therapy in immobilized hip fracture patients. [2004.04]

Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. [2004.01]

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. [2004]

Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. [2003.12]

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. [2003.12]

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. [2003.10]

Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. [2003.07]

Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis. [2003.06]

Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. [2003.05]

Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. [2003.03]

Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. [2003.03]

Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. [2003]

Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy. [2003]

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. [2002.12]

The effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women. [2002.10]

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. [2002.09]

COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. [2002.03]

A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. [2002.03]

Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy. [2001.10]

Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. [2001.03]

Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. [2001.01]

Effect of administration of lipoprostaglandin E(1) on physical activity and bone resorption in patients with neurogenic intermittent claudication. [2001]

Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis. [2001]

Analgesic effect of etidronate on degenerative joint disease. [2001]

Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. [2000.12]

Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. [2000.12]

Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. [2000.07]

Prevention of early postmenopausal bone loss with cyclical etidronate. [2000.05]

Acute effects of etidronate on glucocorticoid-induced bone degradation. [2000.05]

The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study. [2000.03]

A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. [2000]

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. [1999.05]

Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. [1999.04]

The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. [1999]

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. [1998.12]

Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. [1998.06]

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. [1998.05]

Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. [1998.04]

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. [1997.12]

The effect of weight change on DXA scans in a 2-year trial of etidronate therapy. [1997.11]

Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. [1997.09]

Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. [1997.09]

Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. [1997.09]

Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) [1997.09]

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. [1997.08.07]

The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. [1997.08]

Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. [1997.07]

Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study. [1997.07]

The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. [1997.06]

Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? [1997.06]

Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury. [1997.03]

Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. [1997.03]

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. [1997.02]

Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. [1997.02]

Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. [1997]

The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. [1997]

Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. [1996.09]

A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. [1996.07]

Clinical effect of etidronate disodium (EHDP) on heterotopic ossification following total hip arthroplasty. [1995.12]

Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. [1995.07]

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. [1995.06]

Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. [1995.04]

Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. [1994.10]

A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. [1994.07]

Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. [1994.04]

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. [1993.12]

Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM). [1993.10]

The effects of etidronate disodium on progressive hearing loss from otosclerosis. [1993.09]

Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report. [1993.04]

The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. [1993.03]

Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. [1993.02]

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. [1992.01]

A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. [1991.08]

Effect of daily etidronate on the osteolysis of multiple myeloma. [1991.08]

Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. [1991.03]

The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime. [1991]

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. [1990.07.12]

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. [1990.05.03]

Effect of etidronate disodium on bone turnover following surgical menopause. [1989.02]

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. [1989.01]

The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study. [1987.02]

Well-designed clinical trials possibly related to Didronel (Etidronate)

Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis. [2013]

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. [2013]

Lipid profiles within the SABRE trial of anastrozole with and without risedronate. [2012]

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. [2012]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017